RANI vs. HOWL

In the year-to-date period, RANI achieves a -59.34% return, which is significantly lower than HOWL's -8.11% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Rani Therapeutics Holdings, Inc. (RANI) and Werewolf Therapeutics, Inc. (HOWL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current RANI Sharpe Ratio is -0.79, which is comparable to the HOWL Sharpe Ratio of -0.64. The chart below compares the historical Sharpe Ratios of RANI and HOWL, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither RANI nor HOWL has paid dividends to shareholders.

The maximum RANI drawdown since its inception was -98.62%, roughly equal to the maximum HOWL drawdown of -96.90%. Use the drawdown chart below to compare losses from any high point for RANI and HOWL.

Rani Therapeutics Holdings, Inc. (RANI) has a higher volatility of 46.88% compared to Werewolf Therapeutics, Inc. (HOWL) at 32.03%. This indicates that RANI's price experiences larger fluctuations and is considered to be riskier than HOWL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Rani Therapeutics Holdings, Inc. and Werewolf Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.